This event has ended. View the official site or create your own event → Check it out
This event has ended. Create your own
View analytic
Saturday, March 25 • 8:35am - 9:35am
Oculus Virtual Reality View: New Biologics to Improve Outcomes and Quality of Life for Patients with Psoriatic Diseases: The THRIVE Initiative

Sign up or log in to save this to your schedule and see who's attending!

In recent years, the need to improve the structure of psoriatic disease therapy, to define treatment goals, and to measure treatment outcomes by means of parameters of clinical severity and quality of life has intensified. Compared to traditional systemic treatments, current and emerging biologic agents offer the promise of improved disease management and potential reduction in associated comorbidities, along with new safety concerns in long-term psoriasis management. Today, advances in understanding psoriasis pathophysiology have led to a broad spectrum of anti-psoriatic agents, including small molecules and biologics. This session will explore the complexity of immune cell interactions and signaling mechanisms in psoriatic and other immune-related diseases as the basis for newest targeted treatment approaches, including mechanisms underlying itch (an important symptom affecting patient quality of life and work productivity), the role of inflammation in psoriatic and cardiovascular disease, and the mechanisms by which some targeted therapies provide more rapid responses and better patient outcomes. Further, important factors in patient quality of life and self-perception that can help clinicians differentiate among available treatment options will be discussed. Lastly, an individualized approach to psoriatic diseases will be considered that incorporates available targeted and biologic agents in the treatment plan based on existing comorbidities and patient-reported benefits.

  • Review recent advances in the understanding of psoriatic disease pathophysiology
  • Explain the link between psoriatic diseases and cardiovascular disease and the rationale and evidence for screening and management of cardiovascular disease in patients with psoriatic diseases  
  • Describe the mechanisms of action of new and emerging biologics for psoriatic diseases and critically evaluate their efficacy/safety profile in patients with moderate to severe psoriasis and active psoriatic arthritis
  • Discuss the impact of approved and investigational biologics on kinetics of responses, patients’ symptoms, and quality of life, and how to individualize the management of psoriatic diseases based on these factors 

avatar for Joel M. Gelfand, MD, MSCE

Joel M. Gelfand, MD, MSCE

Vice Chair of Clinical Research and Medical Director, Dermatology Clinical Studies Unit; Director, Psoriasis and Phototherapy Treatment Center; Senior Scholar, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Professor of Dermatology, Professor of Epidemiology
Dr. Gelfand is Associate Professor of Dermatology and Epidemiology at the University of Pennsylvania’s Perelman School of Medicine. He is principal investigator of three large National Institutes of Health funded psoriasis projects: The Dermatology Clinical Effectiveness Research Network (DCERN) which evaluates the effectiveness of psoriasis treatments under real world conditions, the Incident Health Outcomes and Psoriasis Events (iHOPE... Read More →

Saturday March 25, 2017 8:35am - 9:35am